Why Is ALAMAR BIOSCIENCES I (ALMR) Stock Up Today?

ALMR stock surged 28.01% to $35.83 on Friday, driven by a series of upgraded analyst price targets and strong earnings results. The company reported better-than-expected second-quarter results, with revenue of $29.427 million beating the $25.940 million estimate. Analysts from JPMorgan, Stifel, and BofA raised their price targets, reflecting confidence in the company’s performance and future outlook. Alamar Biosciences also outlined a 2026 revenue guidance of $116 million to $120 million, significantly above the $113.259 million estimate.

What Happened

The stock opened with a 3.6% gap up at $29.00 and climbed steadily throughout the session. By 12:30 PM ET, the price reached a high of $36.24. The upward momentum was fueled by multiple analyst upgrades. JPMorgan raised its price target to $35 from $32, Stifel increased its target to $32 from $28, and BofA raised its target to $31 from $30. These adjustments followed the company’s Q2 2026 earnings call, where Alamar outlined a 2026 revenue outlook of $116 million to $120 million and a 60% gross margin. The stock closed the session near its high at $35.98 with 0.4 million shares traded.

What The Data Shows

The stock’s performance reflects a sharp deviation from its 52-week range of $18.84 to $29.43. The company’s trailing twelve-month revenue has grown by 195.2%, but it continues to operate at a net loss with a margin of -49.9%. The intraday volume of 0.4 million shares is below the average, suggesting the move is driven more by institutional and analyst activity than broad retail participation. No unusual options activity or insider transactions were reported in the provided data.

What To Watch

The company’s 2026 guidance and recent product launches, such as the NULISAseq Immune 340 Panel, will be key to watch for future momentum. Coverage breadth is also an important factor, as the stock is now the subject of 14 stories from five sources in the last 36 hours.